论文部分内容阅读
目的探讨肺癌脑转移患者采用化疗治疗的临床效果。方法选择我院2009年6月-2011年6月收治的肺癌脑转移患者40例,对照组20例采用VM26单药化疗治疗,观察组20例采用顺伯、异环磷酰胺、伊立替康联合化疗治疗,对两组临床资料行回顾性分析。结果对两组患者行平均1年的随访,观察组为9.5个月中位生存期,为60%1年生存率。对照组为5.7个月中位生存期,为15%1年生存率。两组差异有统计学意义(P<0.05)。结论肺癌脑转移患者采用药物联合化疗治疗,可最大限度延长生存期,改善患者生活质量。
Objective To investigate the clinical effect of chemotherapy in patients with brain metastasis of lung cancer. Methods Forty patients with brain metastases from lung cancer who were treated in our hospital from June 2009 to June 2011 were selected. Twenty patients in the control group were treated with VM26 single-agent chemotherapy. The patients in observation group were treated with cisplatin, ifosfamide and irinotecan Chemotherapy, two sets of clinical data line retrospective analysis. Results The two groups were followed up for an average of one year. The observation group had a median survival of 9.5 months and a 60% 1-year survival rate. The control group was 5.7 months median survival, 15% 1 year survival rate. The difference between the two groups was statistically significant (P <0.05). Conclusion Patients with brain metastases of lung cancer treated with chemotherapy combined with chemotherapy can maximize the survival and improve the quality of life of patients.